Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Moderna Inc.’s stock erased early losses to gain 3.4% on Friday, after the biotech company posted a wider-than-expected ...

Karen Andersen, CFA, is a healthcare strategist for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She is r ...

Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

The company delivered a loss of $2.91 per share, worse than the expected loss of $2.68 per share. Moderna is a biotechnology company primarily engaged in the development and manufacturing of messenger ...

Bengaluru: Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a ...

Cambridge, Massachusetts – home to Harvard and MIT – was the primary source of Chinese researchers who chose to head home.

The SP 500 closed at 6,111.75, just shy of its record 6,118.71, slipping 0.1% on Friday as weak retail sales and inflation ...

The S&P 500 closed just shy of record Friday as data pointing to weakness in the consumer and ongoing inflation concerns weighed upside momentum. At 4:00 p.m. ET ...